What is the risk of developing a serious antibiotic-resistant infection?
Evidence quality 4.25/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 3/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 3/5
- D5 Scope
- 4/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, US adult
1 in 2.6
39% lifetime chance
Most people underestimate this.
range 1 in 3.3 to 1 in 2.1
≈ As likely as
Perceived
Most people understand that antibiotic resistance is a problem in a vague, headline-level way — something that will matter in the future, mostly in hospitals, mostly to other people. The idea that more than one in three US adults will have a serious drug-resistant infection at some point in their lifetime is almost entirely absent from lay risk perception. Resistance is framed as a policy failure, not a personal hazard.
Source: editorial intuition, not polled
Actual
~2.8 million antibiotic-resistant infections per year in the US
US residents
Show derivation
Annual rate: 2,800,000 / 335,000,000 = 0.008358 per person per year. Compounded over 59 adult years: 1 - (1 - 0.008358)^59 = 1 - (0.99164)^59 ≈ 1 - 0.609 = 0.391. This is the probability of experiencing at least one serious AR infection over a lifetime, treating each year as an independent draw at the population rate. The 35,000 annual deaths from AR infections give a separate lifetime fatal AR probability of ~0.006 (1 in 167). The headline figure covers serious infections (not all episodes result in hospitalization), per CDC's 2019 AR Threats Report definition.
Caveats: The 2.8 million figure is a count of infection *events*, not unique persons — a …
The 2.8 million figure is a count of infection *events*, not unique persons — a single individual can contribute multiple episodes in a year, so dividing by the US population overstates the per-person annual probability. The resulting "more than one in three US adults" lifetime figure is therefore an upper bound on personal risk, not a direct per-person estimate. The compound- probability calculation further treats annual incidence as independent across years, which overstates true lifetime risk if a prior infection confers any durable immunity or if recurrent infections cluster in a subset of high-risk patients. Conversely, the calculation uses the US-wide population rate, which understates risk for frequent healthcare users, residents of long-term care facilities, and immunocompromised individuals. The pandemic-era 20% surge in hospital-onset resistant infections suggests the 2019 baseline may undercount the current burden. CDC's 2021-2022 update is narrower in scope (six pathogens, hospital-onset only) and cannot directly replace the 2019 estimate.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Adventure sports
What are the odds of a serious injury from regular participation in surfing, mountain biking, or rock climbing?
Bruxism tooth damage
What are the odds of developing clinically significant tooth damage or TMJ dysfunction from bruxism?
Family caregiver probability
How likely am I to become an unpaid family caregiver — and what is the mental-health toll?
Inheriting AUD risk
If a parent had alcohol use disorder, what are the odds you'll develop alcohol use disorder yourself?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The numbers here are large enough to feel implausible. CDC’s 2019 Antibiotic Resistance Threats Report counted more than 2.8 million serious antibiotic-resistant infections per year in the United States, resulting in more than 35,000 deaths — roughly the same annual toll as traffic accidents. An independent systematic analysis of bloodstream infections published in 2023 found 60,813 deaths associated with bacterial AMR in the US in 2019 — a figure that, though narrower in scope (BSI only), underscores the severity of the resistance burden through a different methodology. Compounded over a 59-year adult lifespan, the population-level rate works out to roughly a 39% lifetime probability of experiencing at least one serious drug-resistant infection — closer to the odds of a coin flip than to the rare-disease framing that most people carry. The fatal subset is narrower: the 35,000 annual deaths translate to a lifetime fatal AR-infection probability of about 1 in 167, comparable in order of magnitude to the lifetime odds of dying in a car crash.
The gap between perceived and actual risk exists partly because resistance is invisible at the clinical encounter. A patient prescribed a course of antibiotics for a UTI or skin infection rarely learns that the organism was resistant, only that the first drug did not work and a second was tried. The category of “infection that required escalation to a harder drug” is rarely coded as a patient-facing event — it shows up in microbiology lab records, not in the conversation most people remember. Resistance is also genuinely distributed unevenly: it concentrates in healthcare settings, in post-surgical patients, in the elderly and immunocompromised, and in communities with high antibiotic use and limited stewardship. The average healthy adult spending minimal time in clinical settings faces a lower per-year rate than the population mean; the math shifts considerably for anyone with a chronic condition that brings them into regular contact with the healthcare system.
The pandemic interval offers the clearest signal that this is not a problem that peaked and is now improving. CDC’s 2021-2022 update found that six hospital-onset resistant infections rose by a combined 20% compared to pre-pandemic levels, peaking in 2021 and remaining elevated in 2022. The mechanism is familiar — pandemic-era disruption to infection control, broad empirical antibiotic use in COVID patients, and delayed elective procedures that concentrated sicker patients in acute-care settings. The 2.8 million baseline is almost certainly a floor for current incidence, not a ceiling. The people at meaningfully elevated risk are not the worried healthy but rather the immunocompromised, the elderly in care facilities, the oncology patients, and anyone facing an invasive procedure — which, at some point, describes most adults.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Centers for Disease Control and Prevention (CDC) — Antibiotic Resistance Threats in the United States, 2019
Antibiotic Resistance Threats in the United States, 2019- Statistic
More than 2.8 million antibiotic-resistant infections occur in the US each year, and more than 35,000 people die as a result- Excerpt
“"More than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. When Clostridioides difficile — a bacterium that is not typically resistant but can cause deadly diarrhea and is associated with antibiotic use — is added to these, the total reaches 3 million infections and 48,000 deaths." ”
- Source data from
- 2019-11-13
- Accessed
- 2026-04-24 · archived copy
- Calculation
- CDC's 2019 AR Threats Report is the most comprehensive national estimate of antibiotic-resistant infection burden. The 2.8 million figure covers 18 pathogens classified as urgent, serious, or concerning threats and is used as the native numerator. The 35,000 deaths figure anchors the fatal sub-probability in the assumptions. Subsequent CDC data (2021-2022 update) found that six hospital-onset resistant infections rose 20% during the COVID-19 pandemic peak, suggesting the 2.8M baseline is a floor, not a ceiling, for post-pandemic years.
-
[2] Open Forum Infectious Diseases / Oxford University Press — Burden of Bacterial Antimicrobial Resistance in United States in 2019: A Systematic Analysis
Burden of Bacterial Antimicrobial Resistance in United States in 2019: A Systematic Analysis- Statistic
60,813 deaths associated with and 14,987 deaths attributable to bacterial AMR in bloodstream infections in the US in 2019- Excerpt
“"In the US, there were 60,813 deaths (95% uncertainty interval [UI]: 32,520–102,231) associated with and 14,987 deaths (95% UI: 7,712–25,156) attributable to bacterial AMR in blood stream infection highest in 2019." The paper concludes: "AMR is a serious burden in the United States, with millions of people acquiring antibiotic-resistant infections each year and tens of thousands dying as a result." ”
- Source data from
- 2023-11-01
- Accessed
- 2026-04-24 · archived copy
- Calculation
- This independent systematic analysis focuses on bloodstream infections (BSI) specifically, finding 60,813 deaths associated with and 14,987 deaths attributable to bacterial AMR in BSI in 2019. The scope is narrower than CDC's all-infection estimate (2.8M infections across 18 pathogens), but the BSI-specific death toll (60,813 associated) exceeds CDC's 35,000 attributable deaths across all infection types, reflecting different attribution methods. The peer-reviewed design — drawing on hospital discharge records, microbiology lab reports, and vital statistics — is methodologically independent of CDC's surveillance network. Used here as corroborating evidence for the severity of AR burden rather than the native numerator.
- Independence
- Methodologically independent of CDC's Threats Report: different data sources (hospital discharge records vs. sentinel surveillance) and different attribution framework, making this a genuine cross-check rather than a recount of the same pipeline.